Clinical Evaluation of the Effect of Encorafenib on Bupropion, Rosuvastatin, and Coproporphyrin I and Considerations for Statin Coadministration
ConclusionThe results from these clinical studies suggest that encorafenib does not cause clinically relevant CYP2B6 induction or inhibition but is an inhibitor of BCRP and may also inhibit OATP1B1/3 to a lesser extent. Based on these results, it may be necessary to consider switching statins or reducing statin dosage accordingly for coadministration with encorafenib.Clinical Trial RegistrationClinicalTrials.gov NCT03864042, registered 6 March 2019.
Source: Clinical Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Breast Cancer | Bupropion | Cancer | Cancer & Oncology | Cholesterol | Clinical Trials | Colorectal Cancer | Crestor | Drugs & Pharmacology | Erbitux | Melanoma | Oral Cancer | Pravastatin | Rosuvastatin | Skin Cancer | Statin Therapy | Study | Wellbutrin